Immune-mediated articles Flashcards
Pregnancy-associated immune-mediated hemolytic anemia in a dog
Fernandez jvecc 2020
42d after matching
Developed IMHA, was on clavamox –> whelped –> PCV started to improve after whelping + clavamox d/c –> clavamox used again later and didn’t cause IMHA
No hyperbilirubinemia + no steroids tx used
Effects of therapeutic plasma exchange on serum immunoglobulin concentrations in a dog with refractory immune-mediated hemolytic anemia
Alyssa M. Scagnelli javma 2018
The decrease and rebound in serum IgG and IgM concentrations following TPE provided evidence that TPE may have the same immunomodulatory effects in dogs
TPE may be a useful alternative in dogs with refractory IMHA when traditional treatments fail
Case-control study of plasma mean platelet component concentration and survival analysis for dogs with immune-mediated hemolytic anemia
Andrea Zoia javma 2018
IMHA dogs- platelets appeared to have been activated to a greater degree (lower plasma MPC) than healthy dogs or sick dogs w/o IMHA
Estimated risk of death for dogs with IMHA decreased by 16% for every unit increase in plasma MPC concentration
Clinical features of precursor-targeted immune-mediated anemia in dogs: 66 cases (2004–2013)
Tara D. Assenmacher JAVMA 2019
Rubriphagocytosis a d collagen myelofibrosis common on BM aspirates
TE events 14% and worsened px (Mst 54d)
73% went into remission, 20% relapsed
MST 913 days
Mortality rate and prognostic factors for dogs with severe anaphylaxis: 67 cases (2016–2018)
M. Ryan Smith JAVMA 2020
Mortality rate 15%
Nonsurvivors had high PT, higher phosphorus, lower temp.
Phos >12, hypoglycemia w/in6h, high PT with PTT >50% RI, need for supplemental dextrose associated w/ death.
Neutrophil Extracellular Traps in Plasma from Dogs with Immune-mediated Hemolytic Anemia
Lawson jvim 2018
Excessive NETs found in IMHA dogs
Development and implementation of a novel immune thrombocytopenia bleeding score for dogs (DOGiBAT)
Kelly M. Makielski, jvim 2018
DOGiBAT: bleeding grades from 0 (none) to 2 (severe) of 9 anatomic sites (cutaneous, catheter or venipuncture bleeding, oral mucosa, intraocular, epistaxis, gastrointestinal, urinary, pulmonary, and intracranial)
- 1= petechia/ecchymoses, single site
- 2= petechia/ecchymoses, >2 location
DOGiBAT scores inversely correlated to platelet count and directly correlated to transfusion requirements + LOH
Long‐term outcome of primary immune‐mediated thrombocytopenia in dogs
K. Simpson JSAP 2018
90% survived to discharge 31% relapsed (median time 79d)
Long-term use of immunosuppressant doesn’t prevent relapse
Detection and dynamics of anti‐platelet antibodies in thrombocytopenic dogs with and without idiopathic immune thrombocytopenia
Sarah Shropshire jvim 2020
20% of 2ry ITP and 100% 1ry ITP tested positive for APA
Presence of APA not associated w/ any outcome measures (response to tx, relapse, prognosis)
Application of therapeutic plasma exchange in dogs with immune‐mediated thrombocytopenia
Lucy Kopecny jvim 2020
TPE 4-4.9 total plasma volumes, associated w/ improvement of bleeding + plt count
Effect of dilution of canine blood samples on the specificity of saline agglutination tests for immune‐mediated hemolysis
Sun and Jeffery jvim 2020
49:1 saline to blood ratio achieved high Sp for IMHA (97%) = don’t use low saline:blood ratio d/t risk of false +vev
Lyophilized platelets versus cryopreserved platelets for management of bleeding in thrombocytopenic dogs: A multicenter randomized clinical trial
Robert Goggs et al jvim 2020
Lyophilized plt was logistically superior (quicker to initiate) and non-inferior to DMSO plts
